Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Entrada Therapeutics Inc.

    NASDAQ: TRDA · Real-Time Price · USD
    7.42
    -0.17 (-2.24%)
    At close: Jun 16, 2025, 3:59 PM
    7.37
    -0.67%
    After-hours: Jun 16, 2025, 07:10 PM EDT
    -2.24%
    Bid 7.25
    Market Cap 281.61M
    Revenue (ttm) 172.22M
    Net Income (ttm) 24.78M
    EPS (ttm) 0.58
    PE Ratio (ttm) 12.79
    Forward PE -1.84
    Analyst Buy
    Ask 8.25
    Volume 65,709
    Avg. Volume (20D) 141,530
    Open 7.58
    Previous Close 7.59
    Day's Range 7.41 - 7.61
    52-Week Range 7.10 - 21.79
    Beta -0.06

    About TRDA

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol TRDA
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for TRDA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    10 months ago
    +11.26%
    Entrada Therapeutics shares are trading higher. Th... Unlock content with Pro Subscription
    news image

    1 month ago · zacks.com

    Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

    Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to earnings of $0.68 per share a year ago.

    news image

    1 month ago · zacks.com

    Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

    Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Add to Watchlist